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Abstract (242 words) 
 
Pre-treatment with reversible acetylcholinesterase (AChE) inhibitors is an 
effective strategy for reducing lethality following organophosphate nerve agent 
exposure. AChE inhibition may have unwanted cardiac side effects, which could 
be negated by adjunctive anti-cholinergic therapy. The aims of the present 
study were to examine the concentration-dependent effects of physostigmine on 
cardiac responses to vagus nerve stimulation (VNS), to test whether adjunctive 
treatment with hyoscine can reverse these effects and to assess the functional 
interaction and electrophysiological consequences of a combined pre-treatment. 
Studies were performed in an isolated innervated rabbit heart preparation. The 
reduction in heart rate with VNS was augmented by physostigmine (1-
1000nmol/L), in a concentration-dependent manner - with an EC50 of 19nmol/L. 
Hyoscine was shown to be effective at blocking the cardiac responses to VNS 
with an IC50 of 11nmol/L. With concomitant perfusion of physostigmine, the 
concentration-response curve for hyoscine was shifted downward and to the 
right, increasing the concentration of hyoscine required to normalise (to control 
values) the effects of physostigmine on heart rate. At the lowest concentration 
of hyoscine examined (1nmol/L) a modest potentiation of heart rate response to 
VNS (+15±3%) was observed. We found no evidence of cardiac dysfunction or 
severe electrophysiological abnormalities with either physostigmine or hyoscine 
alone, or as a combined drug-therapy. The main finding of this study is that 
hyoscine, at concentrations greater than 10-8M, is effective at reversing the 
functional effects of physostigmine on the heart. However, low-concentrations of 
hyoscine may augment cardiac parasympathetic control. 
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acetylcholinesterase; organophosphate nerve agents; vagus nerve; 
physostigmine; hyoscine; scopolamine; eserine 
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1. Introduction 
 
Exposure to highly toxic organophosphate nerve agents results in irreversible 
inhibition of peripheral and central acetylcholinesterase (AChE) resulting in 
acetylcholine accumulation and over-stimulation of muscarinic and nicotinic 
receptors. Symptoms of nerve agent poisoning include hyper-secretion, 
convulsions, respiratory distress, coma and death.  
 
Numerous studies in non-primates and non-human primates have shown that 
pre-treatment with reversible cholinesterase inhibitors, with and without anti-
cholinergics, improves survival and reduces incapacitation after nerve agent 
exposure.(Bonhage et al., 2009; Lim et al., 1991; Lim et al., 1988; Muggleton 
et al., 2003; Philippens et al., 1998; Philippens et al., 2000; von Bredow et al., 
1991; Wetherell et al., 2002; Wetherell, 1994) Pyridostigmine (a quaternary 
compound restricted primarily to the peripheral nervous system) and 
physostigmine (a neutral compound which can more readily pass the blood 
brain barrier) are long acting, but reversible, AChE inhibitors that are effective 
pre-treatments for nerve-agent exposure. While both agents are effective in 
preventing lethality in animal studies, physostigmine appears to be more 
effective against incapacitation, most likely as a consequence of its combined 
central and peripheral actions.(Wetherell et al., 2002) 
 
Common side effects of physostigmine treatment include gastrointestinal 
irritation, urinary urgency, diaphoresis, headaches and vomiting. Potential 
cardiac effects are also important and have been examined in a limited 
number of animal studies, which demonstrate bradycardia and atrio-
ventricular block due to the potentiation of parasympathetic nervous control 
(mediated through the vagus nerve).(James et al., 1979; Lazartigues et al., 
1999) Despite this risk, electrocardiogram monitoring has not been routinely 
performed in pre-clinical studies investigating nerve agent pre-treatment. Co-
administration with competitive muscarinic receptor antagonists (e.g. 
hyoscine) may also reduce symptoms associated with physostigmine 
treatment and overdose.(Moore et al., 2014)  
 
The aims of the present study were - 1) to examine the concentration-
dependent effects of physostigmine on cardiac responses to vagus nerve 
stimulation (VNS), 2) to test whether adjunctive treatment with hyoscine can 
reverse the cardiac effects of physostigmine and 3) to assess the functional 
and electrophysiological consequences of combined drug therapy. Studies 
were conducted in isolated perfused rabbit hearts with intact autonomic 
innervation.  
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2. Methods 
 
2.1 Animal welfare 
All procedures were undertaken in accordance with ethical guidelines set out 
by the UK Animals (Scientific Procedures) Act 1986 and Directive 2010/63/EU 
of the European Parliament on the protection of animals used for scientific 
purposes. Studies conformed to the Guide for the Care and Use of Laboratory 
Animals published by the U.S. National Institutes of Health under assurance 
number A5634-01. Experiments were performed in white adult New Zealand 
rabbits (3.0-4.5kg, n=24) 
 
2.2 Innervated isolated heart  
The studies in this report used the isolated innervated rabbit heart as 
described by Ng et al., with minor modifications.(Ng et al., 2001) Animals 
were pre-sedated using a mixture of ketamine (Ketaset, 10mg/kg, Fort Dodge, 
UK), medetomidine hydrochloride (Sedator, 0.2mg/kg, Dechra, UK) and 
butorphanol (Torbugesic, 0.05mg/kg, Fort Dodge, UK) (i.m.). Anaesthesia was 
induced and maintained using propofol (5mg as required, Rapinovet, 
Schering-Plough Animal Health, UK) with concomitant heparin (1000 units, 
Multiparin, UK). Animals were intubated and ventilated at 60 breaths per 
minute of room air. The major blood vessels leading to and from the thorax 
were ligated and cut. Animals were then killed by an overdose of sodium 
pentobarbitone solution (160mg/kg i.v.), the descending aorta was cannulated 
and the preparation rapidly excised from C1-T12 (on ice). The preparation 
was moved to the perfusion apparatus and retrogradely perfused under 
conditions of constant pressure with an oxygenated (95%02/5%CO2) Krebs-
Henseleit buffer solution containing (in mM): Na+ 140.0, K+ 4.0, Ca2+ 1.8, Mg2+ 
1.0, HCO3
− 24.0, H2PO4
− 0.4, Cl− 121.0, glucose 11.0 and pyruvate 2. Aortic 
perfusion pressure was recorded using a pressure transducer placed in series 
with the perfusion line and was maintained at 80±5mmHg using a feedback 
system (STH Pump Controller, ADInstruments, Oxford, UK) controlling a 
peristaltic pump (D23-Du, Watson-Marlow, Cornwall, UK). Left ventricular 
pressure was assessed using fluid filled balloon inserted to the left ventricular 
cavity. Balloon volume was increased to give a left ventricular end diastolic 
pressure (LVEDP) of 5mmHg. Balloon volume was not altered for the 
remainder of the experiment and hearts were allowed to beat at their intrinsic 
sinus rate. Bipolar electrograms were recorded with one electrode attached to 
the LV apex and one electrode placed on the thorax. Signals were filtered 
using a band-pass filter of 0.1-200Hz (1kHz acquisition).  
 
2.3 Vagus nerve stimulation 
The right vagus nerve was dissected from the surrounding tissues and placed 
upon custom-made silver wire electrodes, connected to a constant voltage 
optically isolated stimulator. Nerves were stimulated at 3X threshold voltage 
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with 2ms square wave pulses. Threshold voltage was defined as the minimum 
voltage required to lower heart rate by 10bpm from baseline values. The 
frequency of VNS was chosen as that which gave a stable reduction in heart 
rate of approximately 80 to 100bpm. A greater magnitude response was 
accepted if stability was deemed to be poor at lower intensities of stimulation. 
In the event that the right vagus was unresponsive the left vagus was used. 
To prevent unwanted activation of the sympathetic nervous system the spinal 
cord was removed in all experiments. 
 
2.4 Solutions 
Physostigmine (physostigmine salicylate salt, 45720, Sigma-Aldrich, UK) and 
hyoscine (hyoscine hydrobromide, S0929, Sigma-Aldrich, UK) were added, 
from concentrated 1mmol/L stock solutions, to a 5-liter volume of Krebs-
Henseliet buffer just prior to perfusion. Stock solutions were freshly prepared 
each day. 
 
2.5 Study protocols 
1. In study protocol 1 the effects of increasing concentrations of 
physostigmine and hyoscine on cardiac functional and 
electrophysiological parameters and responses to VNS were 
investigated in separate hearts (n=8 in each group). Following a 30-
minute stabilization period, hearts were perfused with incremental 
concentrations of physostigmine or hyoscine (1-1000nmol/L). 
Responses to VNS (2-minute stimulation) were tested 10-minutes after 
initiating drug perfusion. 
2. Study protocol 2 examined the effect of increasing concentrations of 
hyoscine (1-300nmol/L) on functional and electrophysiological 
parameters in the presence of 2, 20 or 200nmol/L physostigmine (as 
defined by study protocol 1). Studies were designed to examine the 
facility of hyoscine in reversing the cardiac effects of physostigmine. 
(n=8 in each group) 
 
2.6 Analysis and statistics 
Data were digitized at 1kHz on a 16-channel PowerLab recording system and 
associated LabChart software (v8, ADInstruments, UK). Baseline data 
represent the mean of each variable over a stable 20-second period just prior 
to VNS. Responses to VNS were measured over the 20-second period just 
prior to the cessation of nerve stimulation. Electrocardiogram parameters 
represent the mean of 10 consecutive beats. Heart rate corrected QT index 
was calculated from linear regression of QT interval and heart rate from 
baseline data (see Supplementary Figure 1) using the formula QT measured / 
QT expected *100. Data for predicted QT calculations were taken from values 
following the 30-minute stabilization period from n=12 hearts used in 
physostigmine and hyoscine concentration-response experiments. Reversal 
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concentration was defined as the concentration of hyoscine required to return 
heart rate responses to VNS in the presence of physostigmine to preceding 
baseline values. Hill slope, IC50 and reversal concentration were calculated for 
each experiment by fitting data to the following model (GraphPad Prism v6.0).  
 
Y = Bottom + (Top-Bottom) / (1+10^((Log IC50 - X) * HillSlope)) 
 
Where Top and Bottom are plateaus in the units of the Y-axis (unconstrained). 
Statistical analysis was conducted by paired Student’s t-test (repeated 
measures in the same heart) and 1- or 2-way repeated measures ANOVA 
with Bonferonni post hoc tests, as appropriate (GraphPad Prism v6.0). 
Significance was set at P<0.05. Presented data represent mean±SEM. 
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3. Results 
 
3.1 Physostigmine alone 
The effect of increasing concentrations of physostigmine on cardiac responses 
to VNS are presented in Figures 1 and 2. During VNS, a concentration-
dependent slowing of heart rate was observed with increasing levels of 
physostigmine (see example traces and mean data in Figure 1A, 1B and 1C). 
The maximal effect equated to a 28±5% greater reduction in heart rate in the 
presence of physostigmine (Figure 1B). At concentrations of 100nmol/L and 
greater, physostigmine also caused a slowing of the intrinsic (baseline) heart 
rate (Figure 1D). As a result, the absolute change in heart rate (i.e. baseline 
minus VNS) demonstrated a bi-phasic relationship (Figure 1E), with an initial 
increase, attributed to the greater slowing of heart rate during VNS, followed by 
a decrease, with higher concentrations of physostigmine, when the intrinsic 
heart rate began to fall. Relative heart rate during VNS, expressed as a 
percentage of control values, demonstrated a sigmoidal relationship - with an 
IC50 of 19nmol/L. At the top end of the physostigmine concentration-range we 
observed a slowing on the rate of recovery with the cessation of nerve 
stimulation. This is evidenced by the increase in time to 75% recovery of heart 
rate following VNS in Figure 1F (see also example traces in Figure1A). 
Fasciculations of the skeletal muscles of the neck and thorax were commonly 
observed with physostigmine concentrations in the range of 500-1000nmol/L.  
 
Peak left ventricular pressure (LVP) was stable throughout testing (Figure 1G), 
with a negligible increase in left ventricular end diastolic pressure (LVEDP) over 
the study protocol (data not shown). VNS was associated with an increase in 
peak LVP, the magnitude of which decreased over the course of the experiment 
with increasing concentrations of physostigmine (Figure 1G, overall effect; 
P<0.01).  
 
VNS was associated with an increase in the QT interval (Figure 2A, overall 
effect; P<0.0001), with no change in QT index (Figure 2B), indicating that QT 
prolongation during VNS occurred as a consequence of the slowing of heart 
rate. The QT interval prolonged with increasing concentrations of 
physostigmine, in a manner related to the slowing of the intrinsic (baseline) 
heart rate and, with high-concentrations of physostigmine, rate-independent QT 
prolongation (see the modest increase in the heart rate corrected QT index with 
1000nmol/L physostigmine in Figure 2B). There was no effect of physostigmine 
on PR interval at baseline or with VNS (Figure 2C).  
 
3.2 Hyoscine alone 
Data on the effect of increasing concentrations of hyoscine on cardiac 
responses to VNS are presented in Figures 3 and 4. During VNS, heart rate 
was lower with low-dose hyoscine perfusion (1nmol/L) in 6 of 8 hearts studied, 
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however, there was no overall difference in the magnitude of heart rate 
slowing between conditions (changes from baseline; 87±5 vs. 75±4bpm, 
P>0.05). With higher concentrations of hyoscine, the magnitude of slowing in 
heart rate with VNS was reduced, and heart rate was elevated compared to 
VNS in control conditions (see example traces and mean data in Figure 3A, 
3B and 3C).  Baseline heart rate was unaffected by hyoscine perfusion 
(Figure 3D). Both the absolute heart rate observed during VNS (expressed as 
% of control values), and the change in heart rate from baseline values 
(baseline minus VNS), demonstrated a sigmoidal concentration-response, 
with IC50 values of 11 nmol/L (Figure 3C&E).  
 
The positive inotropic response (Figure 3F) and prolongation of QT interval 
(Figure 4A) with VNS, being a function of heart rate, were abolished with 
increasing concentrations of hyoscine. LVEDP demonstrated a small increase 
over the duration of the experiment, similar to that seen with physostigmine 
(data not shown). Hyoscine had no effect on the heart rate corrected QT index 
(Figure 4B) or PR interval (4C). 
 
3.3 Combined physostigmine and hyoscine 
Data on the effect of increasing concentrations of hyoscine on cardiac 
responses to VNS, in the presence of physostigmine, are presented in Figures 
5-7. High concentration physostigmine (200nmol/L) was associated with a 
slowing of intrinsic (baseline) rate and heart rate during VNS (see Figure 5). A 
similar trend for slower heart rates during VNS was observed with a medium 
(20nmol/L) concentration of physostigmine (P=0.059). Low-concentration 
physostigmine (2nmol/L) was not associated with any effect on heart rate. 
Changes in peak LVP mirrored those seen in heart rate, whereby a reduction in 
rate due to VNS was associated with an increase in contractile force (Figure 5). 
As the heart rate response to VNS was inhibited, by increasing concentrations 
of hyoscine, so was the associated positive inotropic response. [Note: Data 
from 1 heart were excluded from functional analysis due to a leak in the 
ventricular balloon]. 
 
Normalised concentration-response curves for the effects of hyoscine on heart 
rate during VNS, with 3 physostigmine concentrations and for controls (from 
study protocol 1), are presented in Figure 6A. Increasing the background 
concentration of physostigmine was associated with a downward and rightward 
shift in the concentration-response curve for hyoscine (expressed as a % of 
heart rate during VNS in control conditions). As a consequence, the IC50 and 
reversal concentration for hyoscine (i.e. the concentration of hyoscine required 
to normalise to control values the effects of physostigmine on heart rate) were 
greater in the presence of physostigmine (Figure 6B&C). In the case of a 
20nmol/L physostigmine, a concentration of 12±1nmol/L hyoscine was required 
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to reverse its effects on heart rate. Hill slopes were comparable between groups 
(Figure 6D). 
 
In all experimental groups (control, 2, 20 & 200nmol physostigmine), low 
concentrations of hyoscine (1nmol/L) were found to potentiate the heart rate 
response to VNS. Of 32 experiments, 28 demonstrated a greater slowing of 
heart rate following low-concentration hyoscine perfusion (see Figure 7). This 
equates to a 15±3% greater slowing of heart rate versus VNS in control 
conditions (paired t-test, P<0.0001).  
 
There was no observable effect of combined physostigmine and hyoscine on 
electrocardiogram parameters, except for the influence of hyoscine on heart 
rate (data not shown).  
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4. Discussion 
 
The main finding of this study is that hyoscine is effective at reversing the 
functional effects of physostigmine on the heart and that combined drug therapy 
has no obvious adverse effect on left ventricular performance or 
electrophysiological parameters. However, there are some potential exceptions 
to this overall conclusion; namely, that low-concentration hyoscine may act to 
augment cardiac parasympathetic control and the competitive nature of 
muscarinic antagonism by hyoscine.  
 
The parasympathetic nervous system innervates the heart at the sinoatrial 
node, atrio-ventricular node and ventricular tissue through the vagus nerve. 
Acetylcholine, released from efferent nerve endings, binds to muscarinic 
receptors resulting in pacemaker inhibition and membrane hyperpolarization. 
This mediates the major actions of the vagus nerve i.e. slowing of heart rate 
and increased conduction delay through the atrioventricular node (note; the PR 
interval is affected by both heart rate and the vagus nerve, which act in 
opposition, and does not change during VNS in the absence of cardiac 
electrical pacing). Through the baroreceptor reflex the vagus is an important 
determinant of central blood pressure by feedback regulation of cardiac output. 
Consequently, effects on cardiac function are one of the most clinically 
important potential side effects of AChE inhibition. In the present study, we 
demonstrate a concentration-dependent action of physostigmine on the heart 
rate responses to VNS in the isolated rabbit heart. As predicted by its 
cholinergic action, physostigmine potentiated the magnitude of heart rate 
slowing in response to a fixed intensity of VNS. This is likely due to the 
prevention of acetylcholine hydrolysis and a resultant increase in the 
concentration and duration of action of acetylcholine at the synapse. The 
observation that high-concentration physostigmine lowers intrinsic heart rate 
implies a basal level of acetylcholine release and degradation in the 
Langendorff preparation in the absence of nerve stimulation.  
 
With increasing concentrations of physostigmine, a downward and rightward 
shift in the concentration-response to hyoscine was observed. As a result, a 
greater concentration of hyoscine was required to offset the cardiac effects of 
increasing concentrations of physostigmine. This likely reflects that 
accumulated acetylcholine, secondary to AChE inhibition, acts to compete 
with hyoscine, a competitive muscarinic antagonist, for binding to the 
muscarinic receptors. Therefore, the concentration of hyoscine required to 
overcome the effects of physostigmine will vary depending on the 
concentration of physostigmine in the blood. 
 
In the present study we observed a small, but statistically significant, 
augmentation of heart rate responses following perfusion of low-concentration 
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hyoscine, suggesting a possible selective pre-synaptic effect. There is existing 
evidence that acetylcholine can bind to pre-synaptic muscarinic receptors, 
resulting in feedback inhibition of additional acetylcholine release.(Brodde and 
Michel, 1999; Raczkowska et al., 1983; Wellstein and Pitschner, 1988) 
Experiments by Wellstein and Pitchner (1988) suggest that this 
cholinomimetic action may be mediated by type 1 muscarinic receptors (M1), 
being blocked by pirenzepine, an M1-selective muscarinic antagonist, 
whereas type 2 muscarinic receptors likely mediate post-synaptic inhibition of 
responses to VNS.(Brodde and Michel, 1999; Wellstein and Pitschner, 1988) 
As such, it is possible that low-concentration hyoscine may act to augment the 
effects of physostigmine, when both drugs are used in combination, by 
blocking this feedback pathway. This concept requires that hyoscine have a 
higher affinity for the M1 vs. M2 receptor. Unfortunately, we have been unable 
to find studies on the binding affinity of hyoscine in tissues from the rabbit. 
However, Zheng et al. have reported binding affinities for hyoscine (also 
known as scopolamine) to human M1 and M2 receptors, expressed in 
Chinese hamster ovarian cells.(Zheng et al., 2013) The authors reported Ki 
values of 7.5 and 9.5nmol/L for the M1 and M2 receptor, respectively, 
indicating a greater affinity for the M1 receptor. However, these data 
represent only triplicate measurements and no statistical comparison is 
provided. Augmentation of responses to VNS by low-concentration hyoscine 
may present an additional challenge in the presence of higher concentrations 
of physostigmine (i.e. greater than 10nmol/L). Moreover, low-concentration 
hyoscine may act to potentiate intrinsic cardiac-parasympathetic reflexes (i.e. 
in the absence of physostigmine). Given that the present study was performed 
in isolated rabbit hearts, it is difficult to establish if this small effect represents 
a clinically significant observation (i.e. whether there is a risk for 
haemodynamic compromise in vivo). However, it should be considered that if 
physostigmine plasma concentration were to rise more rapidly than that of 
hyoscine, then it is possible that there may be a transient risk of heart rate 
slowing, even if the ultimate steady-state concentrations for both these agents 
have no combined effect on heart rate. 
 
Importantly, we observed no evidence of severe cardiac dysfunction or 
electrophysiological abnormalities with either physostigmine / hyoscine alone 
or with combined drug-therapy. The modest prolongation of heart rate 
corrected QT index at 1000nmol/L physostigmine may indicate off target 
channel effects, however, this is unlikely to have any functional significance 
with respect nerve agent pre-treatment. At this concentration range, 
physostigmine was associated with spontaneous fasciculations of the skeletal 
muscles of the neck and thorax, indicative of over stimulation of the nicotinic 
receptors. Clearly, this is far in excess of clinically efficacious plasma 
concentrations of approximately 100pg/mL.(Möller et al., 1999) 
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The finding that VNS caused an increase in LVP appears at odds with 
previous reports suggesting that vagal stimulation decreases ventricular force 
in the rabbit heart.(Brack et al., 2006; Ng et al., 2001; Winter et al., 2015) 
However, Ng et al (2006) reported a bi-phasic force-frequency response, 
consisting of an initial increase followed by a secondary decrease in 
ventricular force with increasing heart rate. (Brack et al., 2006) Baseline heart 
rates were markedly greater in our study than in previous studies (perhaps 
due to improved perfusion) and so it stands to reason that hearts may be 
initially operating on the downward slope of the bi-phasic force-frequency 
curve.(Brack et al., 2006; Ng et al., 2001; Winter et al., 2015) However, we 
cannot rule out that the positive inotropic response to VNS reflects the low 
oxygen carrying capacity of the Krebs buffer and resulting improved 
energetics when heart rate is slowed. The influence of hyoscine and 
physostigmine on the inotropic response to VNS are likely to be secondary to 
effects on heart rate (i.e. a loss of heart rate response to VNS in the case of 
hyoscine and a fall in baseline heart rate in the case of physostigmine), 
however, this would need to be confirmed in experiments utilizing electrical 
pacing to control for the effect of heart rate.  
 
4.1 Study limitations 
The choice of a cumulative dosing protocol and the duration of drug perfusion 
used in the present study was based on observations from preliminary 
experiments; assessing the stability of nerve responses over time and rate of 
drug washout. On this basis, experiments were limited to a total duration of 
120-minutes. However, we did not perform preliminary experiments to 
examine the rate of onset of action of either physostigmine or hyoscine, which 
may influence our results (e.g. accuracy of EC50/IC50 estimates). If, for 
example, the rate of inactivation of AChE was sufficiently slow, the effect of 
physostigmine at low-doses may have been underestimated. Similarly, we 
cannot discount cumulative effects - resulting from longer-term exposure to 
physostigmine or hyoscine. In previous work, we reported the time for 
inactivation and reactivation of actetylcholinesterase in red blood cells treated 
with 100nmol/L of physostigmine.(Wetherell and French, 1991) The results 
showed that acetylcholinesterase activity was reduced by 74% within 3-
minutes of the addition of physostigmine, with a peak inhibition of 81% by 14-
minutes. Therefore, at least with higher concentrations of physostigmine, near 
maximal inhibition is likely to be achieved within 10-minutes of drug perfusion 
– as used in the present study. In previous work, the rate of reactivation of 
acetylcholinesterase (i.e. decarbomoylation) was substantially slower than the 
rate of inactivation, with a time course of several hours.(Wetherell and French, 
1991) A such, a non-cumulative concentration-response, starting at the 
highest concentration of physostigmine, would not be possible within a 
suitable timeframe for experiments in isolated hearts  
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The isolated innervated heart provides a simplified model system for the study 
of cardiac parasympathetic control. However, our main finding, that hyoscine 
can reverse the neuro-cardiac actions of physostigmine, does not necessarily 
predict the action of physostigmine and hyoscine in the intact whole system 
and should be confirmed by in vivo studies - either by direct stimulation of the 
parasympathetic vagus nerve or by other methods. One alternative approach 
would be to assess baroreceptor reflex gain before and after drug exposure, 
by use of vasoactive compounds (e.g. phenylephrine), and the simultaneous 
measurement of systemic blood pressure and heart rate.(Wang, 1994) Beat-
to-beat oscillations in heart rate, known as heart rate variability, can also be 
used to assess the level of sympathetic and parasympathetic tone, albeit 
indirectly.(Stein et al., 1994) Alternatively, direct electrical recordings could be 
made in the sympathetic stellate ganglia and parasympathetic vagus nerve, 
before and after drug exposure.(Ogawa et al., 2007) 
 
5. Conclusion(s) 
In conclusion, we find that hyoscine is a safe and effective agent for the 
reversal of unwanted cardiac effects of physostigmine treatment. However, 
there is the possibility, albeit slight, that low-concentration hyoscine may act to 
potentiate the cardiac actions of physostigimine. 
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7. Figure legends 
 
Figure 1. Functional responses to vagus nerve stimulation in the presence of increasing 
concentrations of physostigmine. A) Representative traces demonstrating heart rate response 
to vagus nerve stimulation (VNS) with 1, 10, 100 and 1000nmol/L physostigmine (in a single 
experiment). Dotted lines denote 75% recovery of heart rate on the cessation of nerve stimulation. 
Spikes reflect ectopic beats. B) Mean data demonstrating change in heart rate during VNS with 
increasing concentrations of physostigmine. C&D) Mean data demonstrating baseline heart rate 
(C) and heart rate during VNS (D) (expressed as a % of control values). E) Calculated change in 
heart rate (baseline minus VNS) at each concentration of physostigmine. F) Mean data on time to 
75% heart rate recovery following the cessation of VNS with increasing concentration of 
physotigmine. G) Peak left ventricular pressure (LVP) at baseline and during VNS with increasing 
concentration of physostigmine. Data represent mean ± SEM. Statistical comparisons by one- (C-
F) or two-way (B&G) repeated-measures ANOVA, with Bonferonni post-hoc tests. Different from 
control (baseline); ^P<0.05. Different from control (VNS); *P<0.05. Different from 1nmol/L 
physostigmine; &P<0.05.  (n=8). 
 
Figure 2. Electrophysiological responses to vagus nerve stimulation with physostigmine. 
Mean data of QT interval (A), QT index (B) and PR interval (C) at baseline and just before the 
cessation of VNS with incremental increases in physostigmine concentration (separate 
experiments). Data represent mean ± SEM. Statistical comparisons by two-way repeated-
measures ANOVA, with Bonferonni post-hoc tests. Different from control (baseline); ^P<0.05. 
Different from control (VNS); *P<0.05. (n=8).  
 
Figure 3. Functional responses to vagus nerve stimulation in the presence of increasing 
concentrations of hyoscine. A) Representative traces demonstrating heart rate response to 
vagus nerve stimulation (VNS) with 1, 10, 100 and 1000nmol/L hyoscine (in a single experiment). 
B) Mean data demonstrating change in heart rate with VNS at increasing concentrations of 
hyoscine. C&D) Mean data demonstrating baseline heart rate (expressed as a % of control values) 
(C) and heart rate during VNS (D). E) Change in heart rate. F) Peak left ventricular pressure (LVP) 
at baseline and during VNS with increasing concentration of physostigmine. Data represent mean 
± SEM. Statistical comparisons by one- (C-E) or two-way (B&F) repeated-measures ANOVA, with 
Bonferonni post-hoc tests. Different from control (baseline); ^P<0.05. Different from control (VNS); 
*P<0.05. Different from 1 nmol/L hyoscine; &P<0.05.  (n=8). 
 
Figure 4. Electrophysiological responses to vagus nerve stimulation with hyoscine. Mean 
data of QT interval (A), QT index (B) and PR interval (C) at baseline and just before the 
cessation of VNS with incremental increases in hyoscine concentration (separate experiments). 
Data represent mean ± SEM. Statistical comparisons by two-way repeated-measures ANOVA, 
with Bonferonni post-hoc tests. *P<0.05 statistically significant vs. relevant control. (n=8).  
 
Figure 5. Functional responses to vagus nerve stimulation in the presence of physostigmine and 
increasing concentrations of hyoscine. Mean data demonstrating change in heart rate (left) and peak left 
ventricular pressure (LVP, right) with vagus nerve stimulation (VNS) in the presence of a fixed concentration 
of physostigmine and increasing concentrations of hyoscine. Data from 3 groups; A&B) 2nmol/L 
physostigmine, C&D) 20nmol/L physostigmine and E&F) 200 nmol/L physostigmine. Data represent mean ± 
SEM. Statistical comparisons by two-way repeated-measures ANOVA, with Bonferonni post-hoc 
tests. Different from control (baseline): ^P<0.05. Different from control (VNS): *P<0.05. (n=8, all groups) 
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Figure 6. Concentration-response curves for hyoscine in the presence of physostigmine. A) 
Mean data demonstrating the effect of increasing concentrations of hyoscine on changes in heart 
rate during VNS in the presence of 0, 2, 20 and 200nmol/L physostigmine (PHY). Data are 
normalised as a percentage of the control response in each heart. Control data (0nmol/L) are 
derived from Study Part A. B-D) Mean data of IC50, reversal concentration and hill slope for 
hyoscine in each condition. Data represent mean ± SEM. Different from 1nmol/L hyoscine; 
*P<0.05. Statistical comparisons by one-way repeated-measures ANOVA, with Bonferonni post-
hoc tests. Different from control (0nmol/L); ^P<0.05. Different from 2nmol/L physostigmine; 
&P<0.05. (n=8, all groups) 
 
Figure 7. Potentiation of heart rate responses by low-concentration hyoscine. Scatterplot 
showing data from 32 experiments, demonstrating a larger magnitude of heart rate slowing with 
vagus nerve stimulation following perfusion of low concentration (1nmol/L) hyoscine. Data 
represent the change in heart rate in response to vagus nerve stimulation from control or with 1 
of 3 concentrations of physostigmine (2, 20 & 200nmol/L) with and without concomitant low-
concentration hyoscine. Statistical comparisons by Student’s paired t-tests. Different from 
control (CNT) / physostigmine (PHY); *P<0.05. Data represent mean ± SEM. 
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